Ads by Google:


Categories

No categories found.


Celiac.com Sponsor:
No popular authors found.











No popular articles found.
Celiac.com Sponsor:

Celiac Disease Research Projects, Fundraising, Epidemiology, Etc.

This category deals with various proposed and ongoing research projects, including the any fundraising for those projects, and also covers research regarding celiac disease epidemiology.

    (Page 3 of 5)   « Prev  1  2  
    3
      4  5  Next »

    Photo: CC--Karen O'D.

    In an effort to assess rising rates of celiac disease, and an increasing popularity of gluten-free food products, a team of researchers recently conducted a survey.



    Photo: CC--Ed Yourdon

    Celiac disease seems to be on the rise in the United States, with recent population-based data suggest a sharp increase in rates over the last several decades.



    Photo: CC--Carolina Biological Supply

    Data from Alvine's Phase 2A trial of its main celiac disease compound, ALV003, show that ALV003, orally administered to celiac disease patients on a gluten free diet, significantly reduces gluten-triggered intestinal mucosal damage.



    Image: CC-FDAgov
    The U.S. Food and Drug Administration (FDA) is gathering information on drug ingredients derived from wheat, rye or barley, to help people with celiac disease make better-informed decisions when buying drugs and other health products.


    Photo: CC - pedrosimeoes7
    Evidence from numerous epidemiological studies supports the idea that celiac disease is not a disease that largely affects children, but is actually a disease that can affect people of any age. Several recent studies suggested that a majority of patients are now diagnosed after age 50.


    Photo: CC--DoNotLick
    The same ultrasound technology that helps doctors and expectant parents to view a developing baby might soon literally mean a better gluten-free bun in the oven.


    Photo: CC - Montage Communications
    Alvine Pharmaceuticals, Inc. has announced that efficacy data from its Phase 2a clinical trial of ALV003 shows that oral ALV003, administered as part of a gluten free diet, reduced gluten-induced intestinal mucosal damage in people with well-controlled celiac disease.


    Photo: CC--SLU Madrid Campus
    A drug to help relieve us from the harmful effects of gluten exposure. Celiac patients are closer than ever to having such a drug on the market.


    Photo - CC: rdecom
    Alvine Pharmaceuticals claims that Phase 2a clinical trial of ALV003 demonstrates the drug's ability to mitigate gluten-triggered intestinal mucosal damage in serologically negative celiac disease patients who followed a gluten-free diet for one or more years.


    Photo: CC- Jason McHuff
    According to recent estimates, three million Americans suffer from celiac disease—approximately 1% of the population, and only three percent of them have to this writing been correctly diagnosed.


    Photo: CC-RDECOM

    Through the hard work and concerted efforts of many support groups and individuals throughout the US, along with the generosity of Instituto Di Ricerca in Italy, research funding was accumulated. Early in the Twenty-First Century, under the auspices of the Center for Celiac Disease Research, a new epoch in celiac disease awareness was born.



    According to recent estimates, 3 million Americans suffer from celiac disease - approximately 1% of the population, and only three percent of them have to this writing been correctly diagnosed. As startling as that sounds to us all, according to a news article on Medscape Today, the incidence of celiac disease has increased markedly over the last three decades, perhaps even as fourfold, and studies are suggesting the incidence may actually be higher than 1% of the population.



    The interplay among the different immune cells mediating intestinal inflammation in celiac disease is complicated indeed. A subset of T regulatory (Treg) cells that express the Foxp3 protein are present in higher numbers in the intestines of patients with active celiac disease than in healthy controls.


    Through the hard work and concerted efforts of many support groups and individuals throughout the US, along with the generosity of Instituto Di Ricerca in Italy, research funding was accumulated. Early in the Twenty-First Century, under the auspices of the Center for Celiac Disease Research, a new epoch in celiac disease awareness was born. Spearheaded by Dr. Alessio Fasano and several other prominent gastroenterologists, a large multi-center study was undertaken and the rate of celiac disease in the general U.S. population was determined to be at least 1 in 133



    Photo courtesy of Walter and Eliza Hall Institute.
    A new vaccine for celiac disease repeated exposure to toxic peptides to induce T cell tolerance of dietary gluten.


    New study looks at prevalence of CD in the Mediterranean Area. Photo: Jefferson Adams
    A international team of researchers recently set out to estimate the global burden related to undiagnosed Celiac Disease in the Mediterranean Area, as computed by morbidity, mortality and crude health cost.


    New study reveals high rate of celiac disease in Iran.
    Celiac disease was presumed to be rare in Iran because of low awareness and a low index of suspicion. However new epidemiological data show that celiac disease is a common disorder in Middle Eastern countries, particularly Iran.


    Cephalon may one day offer celiac disease treatment. Photo: CC-Calsidyrose

    Cephalon has signed an agreement that gives the company the option to purchase a potentially promising new treatment for celiac disease, called larazotide, from Alba Therapeutics.



    New study reveals higher prevalence of celiac disease.
    A team of researchers recently set out to assess rates of celiac disease and the benefits of screening in the general adult population in certain geographically isolated areas.

    A group of researchers in India recently conducted a community-based study on the prevalence of celiac disease in the northern part of India.

    (Page 3 of 5)   « Prev  1  2  
    3
      4  5  Next »